Individualizing Initial HCV Therapy

Led by Tram T. Tran, MD, a panel of experts discusses their approach to individualizing initial HCV therapy based on key disease and patient characteristics that have an impact on treatment choice, including HCV genotype, race, cirrhosis, comorbidities, and comedications.
Kristen Marks, MD
Nancy Reau, MD, FAASLD, AGAF
Norah Terrault, MD, MPH
Tram T. Tran, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.3 Nursing contact hours
Pharmacists: 1.3 contact hours (0.13 CEUs)
Released: July 12, 2017 Expiration: July 11, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate the results of clinical studies of approved HCV treatments into optimized management strategies for both treatment-naive and DAA-experienced HCV-infected patients
  • Apply key guidelines and study data to ensure appropriate, individualized management for diverse patient populations with HCV and/or HBV infection, based on individual patient factors/comorbidities
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C and B on future patient management strategies

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kristen Marks, MD, has disclosed that she has received funds for research support (paid to her institution) from Bristol-Myers Squibb, Gilead Sciences, and Merck.
Nancy Reau, MD, FAASLD, AGAF

Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support from AbbVie.
Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Biotest, Gilead Sciences, Merck, and Mylan Pharmaceuticals and funds for research support from AbbVie, Biotest, Bristol-Myers Squibb, Gilead Sciences, and Merck.
Tram T. Tran, MD

Medical Director of Liver Transplant
Comprehensive Transplant Center
Cedars Sinai Medical Center
Professor of Medicine
Division of Gastroenterology
Geffen UCLA School of Medicine
Los Angeles, California

Tram T. Tran, MD, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Staff

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer Blanchette, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for HCV specialists, infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

1.3 contact hours may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Credit Designation

This program is assigned ACPE Universal Activity #0797-9999-067-H01-P. This program is designated for up to 1.3 contact hours (0.13 CEUs) of continuing pharmacy education credit.

Type of Activity Application

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 12, 2017, through July 11, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides from Mark S. Sulkowski, MD, on selecting optimal DAA and antiretroviral combinations for patients with HCV/HIV coinfection.

Mark S. Sulkowski, MD Released: July 20, 2018

CME-certified education from Mark S. Sulkowski, MD, on choosing HCV and antiretroviral regimens for patients with HCV/HIV coinfection.

Mark S. Sulkowski, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 20, 2018 Expiration: July 19, 2019

CME-certified expert panel discussion of controversial issues in the management of HBV and HCV infection.

Norah Terrault, MD, MPH
Program Director
Paul Martin, MD Christian B. Ramers, MD, MPH Nancy Reau, MD, FAASLD, AGAF
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 6, 2018 Expiration: July 5, 2019

Norah Terrault, MD, MPH
Program Director
Paul Y. Kwo, MD Paul Martin, MD Christian B. Ramers, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 6, 2018 Expiration: July 5, 2019
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grants provided by
AbbVie
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?